
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Arya Roy, MBBS, discusses breakthroughs and adverse effects associated with antibody-drug conjugates in breast cancer.
Arya Roy, MBBS, discusses breakthroughs and adverse effects associated with antibody-drug conjugates in breast cancer.






